Status:
UNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
Brief Summary
Ovarian cancer is the second fatal gynecological cancer. More than 70% of ovarian cancer patients are diagnosed as advanced. Olaparib is the first oral poly adenosine diphosphate-ribose polymerase inh...
Detailed Description
1. Research status at domestic and foreign Ovarian cancer is the second fatal gynecological cancer. More than 70% of ovarian cancer patients are diagnosed as advanced. Standard treatments include ...
Eligibility Criteria
Inclusion
- Patients with primary ovarian cancer, fallopian tube cancer, or peritoneal cancer confirmed by histology.
- Patients who are taking olaparib.
- Patients should voluntarily participate in the trial and provide signed informed consent.
Exclusion
- 1\) Patients who are not currently taking olaparib treatment.
Key Trial Info
Start Date :
January 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT04699006
Start Date
January 21 2021
End Date
January 1 2026
Last Update
June 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061